EC Number   |
Natural Substrates |
|---|
    1.14.15.15 | (24S)-3beta-hydroxy-24-methyl-5alpha-cholesta-8(14),22-dien-15-one + reduced adrenodoxin + H+ + O2 |
the substrate is a potential drug for lowering cholesterol in the treatment and/or prevention of coronary artery disease, but it is rapidly metabolized in the liver |
| 1.14.15.15 | (25R)-5beta-cholestane-3alpha,7alpha,12alpha,27-tetraol + reduced adrenodoxin + O2 |
- |
| 1.14.15.15 | 3beta-hydroxy-5alpha-cholest-8(14)-en-15-one + reduced adrenodoxin + H+ + O2 |
the substrate is a potential drug for lowering cholesterol in the treatment and/or prevention of coronary artery disease, but it is rapidly metabolized in the liver |
| 1.14.15.15 | 5-cholestene-3beta,7alpha-diol + reduced adrenodoxin + O2 |
- |
| 1.14.15.15 | 5beta-cholestane-3alpha,7alpha,12alpha,26-tetraol + reduced adrenodoxin + O2 |
- |
| 1.14.15.15 | 5beta-cholestane-3alpha,7alpha,12alpha-triol + reduced adrenodoxin + H+ + O2 |
- |
| 1.14.15.15 | 5beta-cholestane-3alpha,7alpha,12alpha-triol + reduced adrenodoxin + O2 |
- |
| 1.14.15.15 | 5beta-cholestane-3alpha,7alpha,12alpha-triol + reduced adrenodoxin + O2 |
conversion of cholesterol to cholic acid |
| 1.14.15.15 | 5beta-cholestane-3alpha,7alpha,12alpha-triol + reduced adrenodoxin + O2 |
metabolism of cholesterol |
| 1.14.15.15 | 5beta-cholestane-3alpha,7alpha,12alpha-triol + reduced adrenodoxin + O2 |
mitochondrial cytochrome P450 forms a complex with the substrate |
